Arbutus Biopharma Corporation
Clinical trials sponsored by Arbutus Biopharma Corporation, explained in plain language.
A biopharmaceutical company developing therapies for hepatitis B and other viral diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New combo aims to free hepatitis b patients from daily pills
Disease control CompletedThis Phase 2 study tested an experimental drug called AB-729 combined with pegylated interferon and standard antiviral pills in 43 adults with chronic hepatitis B. The goal was to see if this approach could safely lower hepatitis B surface antigen levels and allow some participan…
Phase 2 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill aims to tame chronic hepatitis b
Disease control CompletedThis early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for sa…
Phase 1 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC